Upload File

faster, better, safer—getting cml treatment right: how to enhance outcomes with precision medicine...

  • Home
  • Health & Medicine
  • Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
40

Upload: pvi-peerview-institute-for-medical-education

Post on 16-Apr-2017

65 views

Category:

Health & Medicine


3 download

Report

TRANSCRIPT

Page 1: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 2: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 3: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 4: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 5: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 6: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 7: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 8: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 9: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 10: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 11: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 12: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 13: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 14: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 15: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 16: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 17: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 18: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 19: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 20: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 21: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 22: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 23: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 24: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 25: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 26: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 27: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 28: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 29: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 30: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 31: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 32: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 33: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 34: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 35: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 36: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 37: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 38: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 39: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era
Page 40: Faster, Better, Safer—Getting CML Treatment Right: How to Enhance Outcomes With Precision Medicine in the TKI Era

PENGARUH TERPAAN BERITA KASUS TKI TERHADAP SIKAP CALON TKI ... · i PENGARUH TERPAAN BERITA KASUS TKI TERHADAP SIKAP CALON TKI UNTUK BEKERJA KE LUAR NEGERI (Studi Deskriptif Kuantitatif

BCR-ABL Point Mutations and TKI Treatment in CML Patients€¦ · Central Journal of Hematology & Transfusion Cite this article: Kimura S, Ando T, Kojima K (2014) BCR-ABL Point Mutations

ASH 2014 CML report€¦ · ASH 2014 CML report Page 3 of 29 9th December 2014 studies suggest that duration of prior TKI therapy is also important. As more studies report it’s

für erwachsene CML-Patienten - uniklinikum-jena.deund+... · Imatinib/Dasatinib/Nilotinib mit Asciminib Ziele • MMR, MR4, MR4 .5 unter TKI plus ABL (6, 12, 18, 24 Monate) • Toleranz

University of Manchester · Web viewTKI discontinuation in the best 10–20% of TKI responders led to relapse rates of 50–60%, reinforcing the need to understand and target CML

Klinik für Hämatologie, Hämostaseologie, Onkologie u ... · Eine ambulant gegebene TKI-Monotherapie in der chronischen Phase der CML kann 8-Jahres Überlebensraten von über 92%

Stopping TKI treatment in CML: Who and when? 13th National CML Patient Forum, Newcastle 11 th October 2014 Prof. Mhairi Copland University of Glasgow

2nd Generation TKI… Frontline Therapy in CMLimedex.com/hematologic-malignancies-debate... · 2nd Generation TKI… Frontline Therapy in CML Elias Jabbour, M.D. A il 2012April 2012

Studie zur Untersuchung der Lebensqualität von CML- Patientenplan.medone.co.kr/70_icksh2019/data/LS04_Susanne_Saubele.pdf · 2019-06-27 · generation TKI discontinuation • Onset

Chronic Myeloid Leukaemia (CML) - CML-Info

Title: Second-Generation Tyrosine Kinase Inhibitors: The ......2011/02/09  · Key words: Nilotinib, tyrosine kinase inhibitor (TKI), chronic myeloid leukemia (CML), dasatinib, bosutinib

TKI resistance in CML cell lines: Investigating resistance pathways · 2014-04-07 · TKI resistance in CML cell lines: Investigating resistance pathways Carine Tang The Melissa White

Abstracts and notes on CML presentations ASH …spirit-cml.org/presentations/ASH 2010 - CML abstracts and...The 1st line ‘TKI wars’: the latest on nilotinib (Novartis), dasatinib

TKI discontinuation in CML

TKI Overview

Living with CML Fertility and Pregnancy · • TKI therapy probably does not significantly effect the fertility of men and women with CML who want to start a family • Children of

Stopping Treatment in CML and dose reduction in clinical ... · Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular

CML: Living with aprograms.rmei.com/llscml611vl2/Slides.pdf · TKI Frontline Therapy in CML Treatment Discontinuation Percentage F/U (mo) IM400 IM800 Nilotinib Dasatinib Bosutinib

Cardio-Oncology in the Service of CML Patientcml.org.il/wp-content/uploads/2018/10/Cardiooncology-CML-meeting... · Chronic Myeloid Leukemia and TKI 2001 Imatinib 2007 Nilotinib 2006

Trial record 1 of 1 for: Endure (ENDURE-CML-IX) · in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5,

FOR ADULTS WITH CHRONIC OR ACCELERATED PHASE CML …synribo.com/pdf/SYNRIBO_Patient_Brochure.pdf · for adults with chronic or accelerated phase cml following 2 or more tki failures

Inferring immunological control mechanisms from TKI dose … · 1 Inferring immunological control mechanisms from TKI dose alterations in CML patients Tom Hähnel 1, Christoph Baldow1,

WhatsApp in CML ? From Cutting Edge to Future Horizons · TKI Discontinuation In CML TKI treatment: Deep and sustained molecular response TKI discontinuation: Treatment-free remission

Title - Allogeneic Transplantation for CML in the TKI … · Web viewLong-term follow-up from the seminal studies continues to report excellent outcomes with estimated 8 year overall

PERLINDUNGAN TKI

Relatório TKI

CML 1CML 2 CML 7 CML 5 CML 4UNL UNL VT ESTDMD 1 … · CML 6 CML 5 CML 4 CML 3 CML 1CML 2 CML 7 CML 10 CML 8 CML 9 ESTD/PAR ESTDMD 1 MD 2 PRIV UNL VT CML 11 MJ PD ST PRIV CML 12 E

Tki Sumiati

Practice Guidelines in Oncology · 2020. 2. 12. · CML Table of Contents Discussion UPDATES CML-1 CML-2 CML-3 CML-4 CML-5 CML-7 CML-6 CML-A CML-C CML-D CML-F CML-D CML-F line therapy

DIVE - TKI

Managing Chronic Myeloid Leukemia - Donate Today! · 2015-09-21 · TKI Frontline Therapy in CML Treatment Discontinuation Percentage F/U (mo) IM400 Nilotinib Dasatinib Bosutinib

Bosutinib in the Treatment of CML · 2G-TKI for Second Line Therapy in CML-CP •39 (7%) transformed to AP (n=26, 5%) or BP (n=13, 2%) while on 2G-TKI OS TFS EFS Overall 66 91 55

CML MDUG-CML/09101E-01 Guide - Myostat Motion Controlmyostat.ca/cmCart_files/repo/download/CML-09101E-01.pdf · 001 CML Overview Chapter 1 1.1. What is CML? CML is a short form of

Selection of 2nd Generation TKI treatment of patients with ... · CML: Optimal therapy • No disease progression • No disease or therapy-related reduction in QoL, time-related

PENELITIAN TKI